For male carriers, periodic clinical examination of the breasts and regular screening for the prostate is necessary to prevent/detect tumour in an early stage. As prostate cancer risk was the most persistent finding for men with BRCA1 or BRCA2 germline mutation in families with cancer history, prostate specific antigen (PSA) and digital rectal examination (DRE) testing are recommended to be performed regularly, at least once a year (Berliner et al., 2013).